Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914594 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Esteban Alejandro Gomez-Gaitan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Doctoral Program, Physiology Department, University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Jalisco, M…. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Apoyo a la Mejora en las Condiciones de Producción SNI y SNCA (PROSNI 2021), Centro Universitario de Ciencias de la Salud (CUCS) de la Universidad de Guadalajara (UDG).
Abstract (Originalsprache)
Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis. No evidence of disease activity based on the absence of clinical relapse, disability progression or radiological activity (NEDA-3) was used to classify the therapeutic response. Patients were classified as follows: (a) controls: patients who achieved NEDA-3; (b) cases: patients who did not achieve NEDA-3. DNA was extracted from peripheral blood leukocytes. HLA-DRB1*0403 genetic variant was analyzed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. NEDA-3 was achieved in 86.7% of MS patients treated with DMTs. Genotype frequencies were GG 50.5%, GA 34.3%, and AA 15.2%. No differences were observed in the genetic variant AA between patients who achieved NEDA-3 versus patients who did not achieve NEDA-3 (48.7% vs. 43.1%, p = 0.6). We concluded that in Mexican patients with MS, HLA-DRB1*0403 was not associated with the therapeutic response to DMTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology Doctoral Program, Physiology Department, University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.
- Neurology Department, Western National Medical Center, Mexican Social Security Institute, Guadalajara 44340, Jalisco, Mexico.
- Institute of Experimental and Clinical Therapeutics, Physiology Department, University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.
- Department of Biomedical Sciences, Tonala University Center, University of Guadalajara, Tonala 45425, Jalisco, Mexico.
- Biomedical Research Unit 02, Mexican Social Security Institute, Guadalajara 44340, Jalisco, Mexico.
- Institute of Biomedical Sciences, Department of Genetics and Molecular Physiology, University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.
ORCID-Profile: Emilio Edsaul Perez-Guerrero, Cesar Arturo Nava-Valdivia, Laura Gonzalez Lopez, Blanca Esthela Rios-Gonzalez, Jazmin Marquez-Pedroza, Miriam Mendez-Del Villar, Alejandra Villagomez-Vega
Förderung
- Apoyo a la Mejora en las Condiciones de Producción SNI y SNCA (PROSNI 2021)
- Centro Universitario de Ciencias de la Salud (CUCS) de la Universidad de Guadalajara (UDG)
Zitieren
APA
Gomez-Gaitan, E. A., Garcia-Ortega, Y. E., Saldaña-Cruz, A. M., Contreras-Haro, B., Gamez-Nava, J. I., Perez-Guerrero, E. E., Nava-Valdivia, C. A., Gallardo-Moya, S., Martinez-Hernandez, A., Gonzalez Lopez, L., Rios-Gonzalez, B. E., Marquez-Pedroza, J., Mendez-Del Villar, M., Esparza-Guerrero, Y., Villagomez-Vega, A., & Macias Islas, M. A. (2023). Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914594
Vancouver
Gomez-Gaitan EA, Garcia-Ortega YE, Saldaña-Cruz AM, Contreras-Haro B, Gamez-Nava JI, Perez-Guerrero EE, et al. Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914594
BibTeX
@article{GomezGaitan2023,
author = {Gomez-Gaitan, Esteban Alejandro and Garcia-Ortega, Yessica Eleanet and Saldaña-Cruz, Ana Miriam and Contreras-Haro, Betsabe and Gamez-Nava, Jorge Ivan and Perez-Guerrero, Emilio Edsaul and Nava-Valdivia, Cesar Arturo and Gallardo-Moya, Sergio and Martinez-Hernandez, Alejandra and Gonzalez Lopez, Laura and Rios-Gonzalez, Blanca Esthela and Marquez-Pedroza, Jazmin and Mendez-Del Villar, Miriam and Esparza-Guerrero, Yussef and Villagomez-Vega, Alejandra and Macias Islas, Miguel Angel},
title = {Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914594}
}
EUVIMED